S. Hartz

发表

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

T. Dilla, M. Núñez, B. Schweikert, 2020, BMJ Open.

Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK

A. Svedbom, S. Hartz, E. Johansson, 2018, Journal of medical economics.

EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis

A. Pickard, M. Gooderham, C. Nicolay, 2017, Journal of medical economics.

Cost-Effectiveness Analysis of Ixekizumab vs. Secukinumab in Sequential Biologic Treatment of Psoriasis in the UK

A. Svedbom, S. Hartz, E. Johansson, 2016 .

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

K. Reich, C. Leonardi, U. Mrowietz, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis

R. Burge, C. Leonardi, B. Zhu, 2017, Journal of medical economics.

A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis

T. Dilla, J. Sacristán, P. de la Cueva, 2019, Actas Dermo-Sifiliográficas (English Edition).

Public Health Policy Decisions on Medical Innovations: What Role Can Early Economic Evaluation Play?

J. John, S. Hartz, 2009, Health policy.

Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical review

Susanne Hartz, Jürgen John, J. John, 2008, International Journal of Technology Assessment in Health Care.

Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study

L. French, K. Reich, G. Micali, 2017, The British journal of dermatology.

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis

A. Ruyssen-Witrand, R. Perry, C. Sapin, 2020, RMD Open.

Clearing up the hazy road from bench to bedside: A framework for integrating the fourth hurdle into translational medicine

W. Rogowski, J. John, Wolf H Rogowski, 2008, BMC health services research.

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

B. Schweikert, C. Malmberg, C. Sapin, 2020, PharmacoEconomics - Open.

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

Denis Getsios, Susanne Hartz, D. Getsios, 2012, BMC Neurology.

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

T. Dilla, A. Svedbom, M. Núñez, 2018, ClinicoEconomics and outcomes research : CEOR.

A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.

T. Dilla, J. Sacristán, P. de la Cueva, 2019, Actas dermo-sifiliograficas.

Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe

J. Gisbert, S. Hartz, H. Knight, 2023, Current medical research and opinion.

Public Health Policy Decisions on Medical Innovations: What Role Can Early Economic Evaluation Play?

J. John, S. Hartz, 2009, Health policy.